ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Merck Pauses Enrollment for Clinical Trials of Investigational, Once-Monthly, Oral Islatravir for Pre-Exposure Prophylaxis of HIV-1 infection
December 09, 2021Merck announced a pause in enrollment for the IMPOWER 22 (MK-8591-022) and IMPOWER 24 (MK-8591-024) Phase 3 clinical studies evaluating investigational, once-monthly, oral islatravir (ISL), a nucleoside reverse transcriptase translocation inhibitor... -
Gilead, Merck sign pact to develop, commercialise long-acting HIV treatment combinations
March 16, 2021Gilead Sciences and Merck, known as MSD outside the US and Canada, announced that they have entered into an agreement to co-develop and co-commercialise long-acting treatments in HIV that combine Gilead’s investigational capsid inhibitor, lenacapavir ...
Pharma Sources Insight January 2025
